Human chronic myelogenous leukemia (CML) and a subset of acute lymphocytic leukemia (ALL) are caused by expression of Bcr-Abl, a fusion gene generated by reciprocal t(9;22)(q34;q11) chromosome translocation. Bcr-Abl-positive leukemias are characterized by premature release of myeloid and lymphoid lineage cells from bone marrow, followed by expansion of these cells in peripheral blood and infiltration of organs such as spleen, liver and lung. The progression of these diseases involves not only accelerated cell proliferation and enhanced cell survival, but also increased cell motility and active invasion of leukemic cells through blood vessel and matrix barriers. The mechanism by which Bcr-Abl induces increased motility and invasion of leukemic cells is not completely understood.
Membrane-type 1 matrix metalloproteinase (MT1-MMP) is a member of transmembrane metalloproteinases, which is responsible for the degradation of a variety of extracellular matrix (ECM).
1 MT1-MMP is also an activator of proMMP2 as well as proMMP13 and is a key regulator of cell migration and invasion. 1, 2 In migrating cells, MT1-MMP is enriched in migration structures such as lamellipodia, whereas in some tumor cells it is found to localize to a specialized migrating/ invasive structure named invadopodium. 3 This polarized membrane distribution of MT1-MMP is believed to be critical for cell migration and tumor metastasis. Although available evidence suggests that the interactions of MT1-MMP with transmembrane adhesion molecules and filamentous actin (F-actin) may contribute to its polarized distribution in tumor cells, 1 the signaling pathways leading to these interactions remain to be elucidated.
Previously, we found that the expression of Bcr-Abl in murine pro-B-cell line Ba/F3 induces the assembly of an abnormal F-actin-enriched structure at the sites adjacent to membrane. 4 This abnormal structure is also enriched with adhesion molecules such as b1-integrin. Given the importance of actin cytoskeleton and transmembrane adhesion molecules in regulation of subcellular distribution of MT1-MMP, 1 we set forth to test if Bcr-Abl-induced formation of the F-actin rich structures affects the membrane distribution of MT1-MMP. Furthermore, because Bcr-Abl-induced formation of the F-actin rich structures is dependent on Abl interactor 1 (Abi1), a key regulator of actin polymerization, we asked if this pathway plays a role in regulation of membrane distribution of MT1-MMP in Bcr-Ablpositive leukemic cells. This was followed by staining with FITC-conjugated secondary antibody. Cells were then counterstained with TRITC-conjugated phalloidin and DAPI to visualize F-actin and nuclei, respectively. The pictures were captured by two-photon confocal microscopy. Bar: 5 mm. CML, chronic myeloid leukemia; DAPI, 4 0 -6 0 -diamidino-2-phenylindole; FITC, fluorescein isothiocyanate. Mononuclear white blood cells isolated from Bcr-Abl-positive CML patients were stained with TRITC-conjugated phalloidin and analyzed by confocal microscopy for F-actin cytoskeleton. Cells isolated from CML patients displayed the actin-enriched structures similar to those found in Bcr-Abl-transformed Ba/F3 cells ( Figure 1a , compare middle panel to lower panel). In contrast, cells isolated from a Bcr-Abl-negative human blood sample showed no such structures (Figure 1a , upper panel). Indirect immunofluorescence staining followed by confocal microscopy analysis revealed that the polarized F-actin structure was enriched not only with Abl tyrosine kinases (Figure 1b Figure 1A) . To confirm that the polarized distribution of MT1-MMP is induced by Bcr-Abl, we also generated a fusion gene encoding for MT1-MMP with green fluorescence protein (GFP) tag at its C terminus. The fusion gene (gfp-mt1-mmp) was introduced into Ba/F3 cells as well as the p185wt cells and the expression of GFP-MT1-MMP in these cells was determined by western blot analysis (Supplementary Figure 1B) . Fluorescence microscopy analysis revealed that the GFP-MT1-MMP displayed a polarized distribution around F-actin rich structures in p185wt cells, but not Ba/F3 cells (Supplementary Figure 1C) . Together, our data indicates that Bcr-Abl induces a translocation of MT1-MMP to the F-actin rich structures in leukemic cells.
Control
To test if the Abi1 pathway is required for Bcr-Abl to induce the polarized distribution of MT1-MMP, we made use of p185DSH3DC, a mutant Bcr-Abl defective in signaling to Abi1. 4 The Ba/F3 cells expressing GFP-MT1-MMP were transformed by p185wt or p185DSH3DC and the expression of the wild-type and mutant Bcr-Abl proteins was confirmed by western blot analysis (Supplementary Figure 2A) . Expression of p185wt, but not p185DSH3DC, induced the F-actin rich structures and recruitment of GFP-MT1-MMP to these structures (Figure 2a, right panel) , suggesting that the polarized distribution of MT1-MMP requires Abi1 signaling. This notion is further supported by the data obtained from a complementary approach. In this experiment, sequence specific small hairpin RNA (shRNA) was used to knock down the expression of Abi1 in p185wt cells that express GFP-MT1-MMP (Supplementary Figure 2B) . The subcellular distribution of GFP-MT1-MMP was then examined by fluorescence microscopy. We found that the knockdown of Abi1 expression significantly impaired Bcr-Ablinduced polarized distribution of GFP-MT1-MMP (Figure 2b) .
Recent studies have shown that MT1-MMP plays a critical role in regulation of human leukocyte migration.
5-7 The observations that Bcr-Abl/Abi1 pathway induces a polarized distribution of MT1-MMP in leukemic cells raised the question (Figure 3b) . Thus, our studies suggest that MT1-MMP may play a role in Bcr-Abl-stimulated leukemic cells migration. In this report, we identified MT1-MMP as a novel downstream target of Bcr-Abl/Abi1 signaling. We show that by activating the Abi1 pathway, Bcr-Abl induces a translocation of MT1-MMP to a membrane-associated structural complex enriched with F-actin and adhesion molecules. Recruitment of MT1-MMP to invadopodia in invasive tumor cells has been reported and is thought to play an important role in tumor metastasis, as it may enhance local ECM degradation and therefore, facilitate tumor cell migration and invasion. 1, 3, 8 Our studies suggest that a similar mechanism may also be utilized by Bcr-Abl-positive leukemic cells. It is notable that the F-actin rich structure induced by Bcr-Abl shares some similarities with invadopodia in that they both appear as a membrane-associated F-actin rich complex consisting of multiple structural/regulatory proteins involved in the regulation of actin cytoskeleton assembly, cell adhesion and ECM degradation. We believe that the studies presented here warrant further investigation of this membraneassociated structural complex found in Bcr-Abl-positive leukemic cells. Precursor B-cell acute lymphoblastic leukemia (B-ALL) represents a heterogeneous group of hematopoietic neoplasms with variable outcome. 1 The cytogenetic profiles, genotype and immunophenotype of the malignant cells have a considerable impact on prognostic stratifications with recognition of low, intermediate and high-risk groups. These stratifications, resulting in risk-adapted therapeutic regimens, underline the crucial importance of biological characteristics in the management of patients with ALL.
In contrast to acute leukemic presentation of Burkitt lymphomas, surface immunoglobulin (sIg) expression is typically absent on these precursor B-ALL cells. 1 In addition, Burkitt leukemia is classically associated with the FAB-L3 morphology and the presence of 8q24 (MYC) translocation. However, rare cases of sIg þ B-ALL with non-FAB-L3 morphology and lacking MYC rearrangement have been reported in both adult and pediatric patients as 'mature B-ALL'. 1, 2 Clonal rearrangements of MLL (mixed lineage leukemia or myeloid/lymphoid leukemia) gene are usually seen in infants' leukemias as well as a majority of therapy-related leukemias, in which it always represents a hallmark for aggressive disease, poor clinical outcome and bad response to treatment with high risk of relapse. 2, 3 Those rearrangements include chromosomal translocations, internal gene duplications, chromosome 11q deletions or inversions, MLL gene insertions into other chromosomes and insertion of genetic material into the MLL gene.
3 The most frequent translocation partner genes for MLL in acute leukemias are AF4, AF9, ENL, AF10 and AF6. In gene expression profiling studies, MLL þ precursor B-ALL shows a profile consistent with an early hematopoietic progenitor that is distinct from conventional B-ALL and acute myeloid leukemia, suggesting that MLL þ precursor B-ALL represents a clinically and molecularly unique entity. 3 Among the cases of mature B-ALL without FAB-L3 morphology and MYC rearrangement reported in children, very few present MLL gene rearrangements and especially the t(9;11) translocation. 2, 4, 5 We here describe an additional series of five cases of such childhood mature B-ALL with MLL rearrangement, four with the t(9;11) translocation and one with the t(10;11) translocation, and focus on their common clinical and biological characteristics.
Clinical data are summarized in Table 1 . A common feature in all cases was the presence of extramedullary involvement at diagnosis, including central nervous system (CNS; n ¼ 2) and renal tumorous enlargement (n ¼ 2). No skin or gums involvement was seen in these patients.
Hematological data are shown in Table 2 . All cases presented with marked blastic infiltration in peripheral blood and massive bone marrow leukemic infiltration with more than 80% of blast cells.
Morphological and cytochemical data are shown in Figure 1 and Table 2 . In the four cases with evidence of t(9;11) translocation, the bone marrow smears at diagnosis showed lymphoblasts with irregular nucleus, large and prominent nucleoli in some cells, microvacuolated cytoplasm without hyperbasophilic aspect and small to intermediate size (15-20 mm). In the case with t(10;11) translocation, the predominant leukemic cells had a round nucleus with lacy chromatin pattern and a small amount of cytoplasm. They were larger than the blast cells with t(9;11) translocation (about 25 mm), but did not appear to present any monocytic differentiation.
No FAB-L3 morphology was present in any of these cases (see Figure 1a) . Blast cells exhibited a high mitotic index. However, no apoptotic figure was seen, confirming the absence of Burkitttype morphology criteria. Myeloperoxydase reaction was negative both at diagnosis and relapse in all patients. Alphanaphthyl-butyrate esterase was performed at diagnosis in only one case and was negative. The blast cells morphology and cytochemistry remained unchanged at relapse (cases 2, 3 and 4) with no switch to FAB-M5-monocytic aspect.
Blast cells exhibited a mature B-cell immunophenotypic profile, that is, CD19 þ , CD20 low , CD22 þ , cIg þ , sIg þ with ml isotype in three patients and mk isotype in two, CD34À, TdtÀ and CD10 þ /À in all of the cases (see Table 3 ). Myeloid and monocytic markers were all negative.
In one case (case 4), some T-cell markers were present at relapse (CD2 and CD5) with a low positivity. In all cases with evidence of relapse, light-chain isotype and maturity B-cell markers remained unchanged when compared to those at diagnosis.
